ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report)'s stock price shot up 4.5% on Tuesday. The company traded as high as $6.38 and last traded at $6.2520. Approximately 1,757,559 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 19,836,211 shares. The stock had previously closed at $5.98.
Analyst Ratings Changes
Several research analysts recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of ImmunityBio in a research note on Thursday, October 15th. Jefferies Financial Group boosted their price objective on shares of ImmunityBio from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Wednesday, October 14th. Wall Street Zen cut shares of ImmunityBio from a "hold" rating to a "sell" rating in a report on Saturday. Piper Sandler reaffirmed an "overweight" rating and set a $16.00 target price on shares of ImmunityBio in a research note on Wednesday, October 14th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of ImmunityBio in a report on Tuesday, October 6th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $16.00.
Check Out Our Latest Report on IBRX
ImmunityBio Stock Up 3.1%
The firm has a fifty day moving average price of $8.55 and a two-hundred day moving average price of $7.96. The stock has a market capitalization of $6.56 billion, a P/E ratio of -5.70 and a beta of 0.17.
Insider Transactions at ImmunityBio
In related news, Director Cheryl Cohen sold 81,056 shares of the stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $10.50, for a total transaction of $851,088.00. Following the sale, the director directly owned 100,309 shares of the company's stock, valued at approximately $1,053,244.50. This represents a 44.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry Simon sold 25,000 shares of the stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $10.75, for a total transaction of $268,750.00. Following the sale, the director directly owned 2,777,788 shares in the company, valued at $29,861,221. This trade represents a 0.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 66.10% of the company's stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. Doliver Advisors LP boosted its position in shares of ImmunityBio by 110.0% in the third quarter. Doliver Advisors LP now owns 210,000 shares of the company's stock worth $1,982,000 after purchasing an additional 110,000 shares during the period. Hussman Strategic Advisors Inc. bought a new stake in shares of ImmunityBio during the 2nd quarter valued at $1,287,000. Tidal Investments LLC bought a new stake in shares of ImmunityBio during the 2nd quarter valued at $2,207,000. SEB Asset Management AB bought a new stake in shares of ImmunityBio during the 1st quarter valued at $18,770,000. Finally, BlackRock Inc. lifted its stake in shares of ImmunityBio by 29.4% during the 2nd quarter. BlackRock Inc. now owns 34,083,262 shares of the company's stock valued at $298,399,000 after buying an additional 7,736,819 shares in the last quarter. Institutional investors own 8.58% of the company's stock.
About ImmunityBio
(
Get Free Report)
ImmunityBio is a biotechnology company that develops immunotherapies for cancer and infectious diseases. Its research combines approaches including immune-modulating biologics, cell therapies and vaccine-based treatments, with a focus on activating the body's natural and adaptive immune responses. The company's lead product, Anktiva (nogapendekin alfa inbakicept-pmln), received U.S. Food and Drug Administration approval in 2024 for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.